De Novo is a pathway for classifying new medical devices that provide reasonable assurance of safety and effectiveness for their intended use through general controls, or general and special controls, but for which there are no legally marketed devices available on the market. Therefore, the De Novo classification is a risk-based classification process.
Devices classified as Class I or Class II through a De Novo classification request can be marketed and used as the initial reference for future Premarket Notification (510(k)) submissions.
Option 1: Upon receiving a high-level non-substantial equivalence (NSE) determination for the 510(k) submission.
Option 2: Determined by the applicant when there are no legally marketed equivalent devices available on the market to serve as a basis for determining substantial equivalence.
Before submitting a De Novo application to the FDA, we assist in preparing and submitting the necessary documentation to the premarket review department and obtaining feedback.
Collaborate with global partners to provide technical documentation compliant with ISO, GLP, and FDA regulations, including the testing data required for medical device submissions. Utilize known data to establish a complete data chain for regulatory authorities, ensuring that medical device data is clear and controllable for submission to regulatory agencies.

